PharmaSynergyRx
February 5-6, 2026
London, UK
https://pharma-synergy-conference.com/pharmasynergy-2026/
News and Events
Subscribe to our press distribution list to receive the latest news about AMW.
Downloads
Upcoming
Events
EuroPLX
March 2-3, 2026
Lisbon, Portugal
https://www.raucon.com/euro-plx/euro-p-l-x-90
EAU Congress
March 13-16, 2026
London, UK
https://eaucongress.uroweb.org/
BIO-Europe Spring
March 23-25, 2026
Lisbon, Portugal
https://informaconnect.com/bioeurope-spring/
CPHI South East Asia
July 8-10, 2026
Bangkok, Thailand
https://www.cphi.com/sea/en/attend/attend/why-attend.html
CPHI Milan
October 6-8, 2026
Milan, Italy
https://www.cphi.com/europe/en/exhibit/book-your-stand-milan.html
Past
Events
Archive
DCAT Week 2025
March 17-20, 2025
New York City, USA
https://dcatweek.org/
AT Uro Congress
May 22-24, 2025
Vienna, Austria
International Partnering in Life-Sciences Society (IPLS)
September 29 – October 1, 2025
Berlin, Germany
https://ipls.online/events/
PODD – Partnership Opportunities in Drug Delivery
October 27-28, 2025
Boston, US
https://poddconference.com/
CPHI Frankfurt
October 28-30, 2025
Frankfurt, Germany
https://www.cphi.com/europe/en/home.html
BIO-Europe
November 3-5, 2025
Vienna, Austria
https://informaconnect.com/bioeurope/
Latest
News
AMW and SAJA Pharmaceuticals sign license and supply agreement for commercialization of AMW’s goserelin implant
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, and SAJA Pharmaceuticals, a leading regional drug manufacturer based in Jeddah, Saudi Arabia, with a presence in the MENA (North Africa and Middle East) states, announced today that they have entered into an exclusive licensing and supply agreement. The agreement covers the commercialization of AMW’s goserelin implant in the Kingdom of Saudi Arabia.
read moreFurther EU Marketing Authorizations for AMW’s Leuprorelin Implant for the Treatment of Hormone-Sensitive Tumors
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that the leuprorelin implant it developed has received additional marketing approvals in two European Union countries. Leuprorelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate cancer, and of certain gynecological diseases. AMW’s leuprorelin implant is now approved as a cost-effective therapy in over ten countries worldwide.
read moreAMW and Mistral sign License and Supply Agreement for Commercialization of AMW’s Goserelin and Leuprorelin implants
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and Mistral Capital Management Ltd, a pharmaceutical company specialized in distribution and promotion of high-quality medicines, today announced that they have entered into a semi-exclusive license and supply agreement (LSA) for the commercialization of AMW’s goserelin and leuprorelin implants in two countries, including Ukraine.
read moreAMW Strengthens Management Team to Support the Company’s Growth Strategy
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has strengthened its management team with the appointment of experienced professionals to head its Research & Development (R&D), Quality and Human Resources (HR) departments.
read moreFurther marketing approvals for AMW’s goserelin implant for the treatment of hormone-sensitive tumors in the EU and Central America
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that its proprietary goserelin implant has received two additional marketing approvals in one country each in the European Union and Central America. AMW’s goserelin implant is the only approved generic implant version to date for AstraZeneca’s originator product Zoladex®1. Goserelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate or breast cancer, as well as certain gynecological diseases. AMW’s goserelin implant is now available to patients in approximately 30 countries worldwide as a cost-effective alternative therapy.
read more